Results 141 to 150 of about 126,909 (281)

Atrial cardiomyopathy

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala   +1 more
wiley   +1 more source

The anti‐fibrotic effects of novel heart failure pharmacotherapies in advanced heart failure patients

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy   +10 more
wiley   +1 more source

Recent Clinical Updates of Hypertrophic Cardiomyopathy and Future Therapeutic Strategies

open access: yesReviews in Cardiovascular Medicine
Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiomyopathy transmitted in an autosomal dominant manner to offspring. It is characterized by unexplained asymmetrical hypertrophy primarily affecting the left ventricle and ...
Mengya Zhao   +7 more
doaj   +1 more source

The relationship between the cannabinoids and cardiac remodelling: A comprehensive review of pivotal mechanisms and emerging evidence

open access: yesBritish Journal of Pharmacology, EarlyView.
Cardiac remodelling and fibrosis after myocardial infarction or during chronic diseases, such as arterial and pulmonary hypertension or diabetes mellitus, continue to be the more important prognostic factors in determining survival, and so the search for effective anti‐fibrotic interventions is an important target for research and therapy in cardiology.
Anna Krzyżewska   +2 more
wiley   +1 more source

Porphyromonas gingivalis GroEL exacerbates orthotopic allograft transplantation vasculopathy via impairment of endothelial cell function

open access: yesMolecular Oral Microbiology, EarlyView.
Abstract Orthotopic allograft transplantation (OAT) is a significant approach to addressing organ failure. However, persistent immune responses to the allograft affect chronic rejection, which induces OAT vasculopathy (OATV) and organ failure. Porphyromonas gingivalis can infiltrate remote organs via the bloodstream, thereby intensifying the severity ...
Chien‐Sung Tsai   +7 more
wiley   +1 more source

Histiocytes: Multifaceted Regulators of Health and Disease

open access: yesVeterinary Clinical Pathology, EarlyView.
ABSTRACT The mononuclear phagocyte system encompasses macrophages, dendritic cells (DCs), and monocytes. Tissue‐resident macrophages and dendritic cells arise during embryogenesis and are replenished either through self‐renewal or by monocytes during inflammation.
Erika J. Gruber
wiley   +1 more source

Impact of SGLT2i on Cardiac Remodeling and the Soleus Muscle of Infarcted Rats

open access: yesAntioxidants
Skeletal muscle changes occur in heart failure (HF). Despite the cardioprotective effects of sodium–glucose co-transporter 2 (SGLT2) inhibitors in HF, their impact on skeletal muscle remains poorly understood.
Lidiane Moreira Souza   +14 more
doaj   +1 more source

Spaceborne and spaceborn: Physiological aspects of pregnancy and birth during interplanetary flight

open access: yesExperimental Physiology, EarlyView.
Abstract Crewed interplanetary return missions that are on the planning horizon will take years, more than enough time for initiation and completion of a pregnancy. Pregnancy is viewed as a sequence of processes – fertilization, blastocyst formation, implantation, gastrulation, placentation, organogenesis, gross morphogenesis, birth and neonatal ...
Arun V. Holden
wiley   +1 more source

Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy

open access: yesNature Cardiovascular Research
AbstractHypertrophic cardiomyopathy (HCM) is an inherited disease of the sarcomere resulting in excessive cardiac contractility. The first-in-class cardiac myosin inhibitor, mavacamten, improves symptoms in obstructive HCM. Here we present aficamten, a selective small-molecule inhibitor of cardiac myosin that diminishes ATPase activity by strongly ...
Hartman, James   +19 more
openaire   +3 more sources

Muscle wasting in cancer cachexia: Mechanisms and the role of exercise

open access: yesExperimental Physiology, EarlyView.
Abstract Cancer cachexia (CC) is a multifactorial disease marked by a severe and progressive loss of lean muscle mass and characterized further by inflammation and a negative energy/protein balance, ultimately leading to muscle atrophy and loss of muscle tissue.
Zoe P. Libramento   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy